Breakthrough Biotech Builders with Katrine Bosley
The Breakthrough Biotech Builders series are curated, invitation only gatherings that convene an elite cohort of Boston’s most successful founders and executives—leaders who have turned visionary concepts into life-saving therapies. Our goal for these discussions is to provide founders & CEOs of biotech companies an opportunity to engage directly with pioneers in the field, and learn from their experience bringing a drug candidate through a successful development path to the clinic.
About Katrine Bosley:
Katrine Bosley has built multiple successful biotechnology companies that have created and developed innovative medicines and life science technologies, including as CEO of Editas Medicine (CRISPR-based genome editing), CEO of Avila Therapeutics (covalent small molecule medicines), Board Chair of Arrakis Therapeutics (RNA-directed small molecules), and founding CEO of DaCapo Brainscience (machine learning discovery in neurodegenerative diseases). She is currently a Venture Partner at Advent Life Sciences. More broadly she has served as a director or chair for numerous public and private life science organizations (Galapagos NV, Genocea Bioscience, Scholar Rock, Biotechnology Innovation Organization [BIO]) and was Entrepreneur-in-Residence at The Broad Institute, VP Business Development at Adnexus Therapeutics/Bristol Myers-Squibb. She had earlier roles at Biogen, Highland Capital Partners, and Alkermes. Katrine is also currently on the Boards of the specialty teaching hospital Massachusetts Eye & Ear, of the Institute of Contemporary Art / Boston, and of Community Servings. She is a graduate of Cornell University.
About the Moderator:
Prof. William (Bill) Chin is the Bertarelli Professor of Translational Medical Science and Professor of Medicine Emeritus at Harvard Medical School. He previously served as Executive Vice President for Science and Regulatory Advocacy and Chief Medical Officer at PhRMA, leading advocacy efforts with the FDA and NIH. Prior to this, he was an Executive Dean for Research at HMS and Senior Vice President for Discovery Research and Clinical Investigation at Eli Lilly, overseeing over 100 drug candidates. A Harvard-trained endocrinologist, Dr. Chin has a distinguished 25-year career at HMS, including roles as Chief of the Genetics Division at Brigham and Women’s Hospital and a Howard Hughes Medical Institute Investigator. He has advised Singapore for over 40 years on developing its biotechnology innovation ecosystem, serving as an active Board Member of A-STAR. In 2023, he received honorary Singapore citizenship for these contributions. Dr. Chin earned his A.B. from Columbia University and M.D. from Harvard Medical School, and has received numerous awards for research, mentorship, and leadership.
About TINS: Technology Innovation Studio (TINS) is an innovation studio that uses systems dynamics models to accelerate innovation. TINS carries out interest groups based programming and builds communities through curated events and complements this with expert-led concierge and consulting services. TINS has interests in venture creation and in doing syndicated investments in early-stage deep-tech companies.
About the Breakthrough Biotech Builders Series: A quarterly series that aims to offer unparalleled insights into the minds of leaders who have successfully and repeatedly translated great ideas into medicines. Previous sessions were held with Dr. Steve Paul https://luma.com/5rfgvqfd, Dr. John Maraganore https://luma.com/z34kjv1p, Dr. Mary Lynne Hedley https://luma.com/55z15vh1, and Dr. Robert S. Langer https://luma.com/tspi1lso
Note: Registration fees contribute toward venue costs and complimentary refreshments.